Analyst Price Target is $5.25
▲ +∞ Upside Potential
This price target is based on 1 analysts offering 12 month price targets for YS Biopharma in the last 3 months. The average price target is $5.25, with a high forecast of $5.25 and a low forecast of $5.25. The average price target represents a ∞ upside from the last price of $0.00.
Current Consensus is
Buy
The current consensus among 1 investment analysts is to buy stock in YS Biopharma. This Buy consensus rating has held steady for over two years.
YS Biopharma Co., Ltd., a biopharmaceutical company, engages in discovering, developing, manufacturing, and commercializing of vaccines and therapeutic biologics for infectious diseases and cancer. The company develops a proprietary PIKA immunomodulating technology platform and a series of product targeting PIKA rabies vaccine, PIKA recombinant COVID-19 vaccine, and PIKA YS-ON-001. It operates in China, the United States, Singapore, the United Arab Emirates, and the Philippines. The company was founded in 2002 and is based in Beijing, China.
Read More